RND3 GTPase cycle

Stable Identifier
R-HSA-9696264
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

RND3 (RHOE) is an atypical RHO GTPase from the RND subfamily. RND3 is constitutively bound to GTP and lacks GTPase activity. No guanine nucleotide exchange factors (GEFs), GTPase activator proteins (GAPs) or guanine nucleotide dissociation inhibitors (GDIs) act on RND3. RND3 is a direct antagonist of ROCK1 kinase activity. RND3 prevents phosphorylation of ROCK1 targets and, similar to RND1, induces stress fiber disassembly. RND3 regulates cell migration, establishment of neuronal polarity, heart development, and myometrium changes during pregnancy. Defective RND3 function is related to cardiomyopathy, hydrocephalus and cancer. Like RND1, RND3 is implicated both as a tumor suppressor and an oncogene in cancer, and can both increase and decrease sensitivity to chemotherapeutic agents, which depends on cancer type and stage. For review, please refer to Jie et al. 2015 and Paysan et al. 2016.

Literature References
PubMed ID Title Journal Year
26756630 Pathophysiological Functions of Rnd3/RhoE

Jie, W, Andrade, KC, Lin, X, Yang, X, Yue, X, Chang, J

Compr Physiol 2015
27555595 Rnd3 in Cancer: A Review of the Evidence for Tumor Promoter or Suppressor

Paysan, L, Piquet, L, Saltel, F, Moreau, V

Mol. Cancer Res. 2016
Participants
Participates
Orthologous Events
Authored
Reviewed
Created
Cite Us!